SALT LAKE CITY, May 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill. Key podium presentations will highlight the safety and validity of the Myriad myRisk® Hereditary Cancer multigene panel test in assessing hereditary cancer risk. Abstracts of the Company’s presentations are available at: abstracts.asco.org.
“We’re excited that the studies with myRisk Hereditary Cancer being presented at ASCO will advance the state-of-the-art of hereditary cancer testing,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. “In particular, our new data provide additional evidence for expanding testing to a broader set of patients at risk for developing hereditary cancers, and for understanding the risks associated with mutations.”
Myriad’s presentations are listed below. Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.
myRisk Hereditary Cancer Presentations
|Title:||Yield of multiplex panel testing exceeds expert opinion and validated prediction models.|
|Date:||Sunday, June 5, 2016, 9:45 - 9:57 a.m.|
|Title:||Ovarian cancer (OC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.|
|Date:||Monday, June 6, 2016, 10:09 - 10:21 a.m.|
|Location:||E450ab, Abstract: 5510|
|Title:||Safety of multiplex gene testing for inherited cancer risk: interim analysis of a clinical trial.|
|Date:||Tuesday, June 7, 2016, 8:36 - 8:48 a.m.|
|Title:||Prevalence of germline mutations in cancer risk genes among unselected colorectal cancer (CRC) patients (pts).|
|Date:||Tuesday, June 7, 2016, 8:12 - 8:24 a.m.|
|Title:||Genetic heterogeneity and survival among pancreatic adenocarcinoma (PDAC) patients with positive family history.|
|Date:||Saturday, June 4, 2016, 8:00 - 11:30 a.m.|
|Location:||Hall A, Abstract:4108, Poster Board 100|
|Title:||Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene cancer panel.|
|Date:||Monday, June 6, 2016, 8:00 - 11:30 a.m.|
|Location:||Hall A, Abstract:1580, Poster Board 403|
Poster Discussion Presentation
|Title:||Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.|
|Date:||Monday, June 6, 2016, 8:00 – 11:30 a.m., Discussion 1:15 – 2:30 p.m.|
|Location:||S404, Abstract:1512, Poster Board 335|
myChoice® HRD: Poster Presentation
|Title:||Clinical significance of homologous recombination deficiency (HRD) score testing in endometrial cancer patients.|
|Date:||Monday, June 6, 2016, 1:00 - 4:00 p.m.|
|Location:||Hall A, Abstract: 5584, Poster Board 407|
Prolaris® Abstract Publication
|Title:||Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index.|
About Myriad myRisk® Hereditary Cancer Testing
The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms in an 850 step laboratory process to evaluate 25 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information visit: https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.
About myChoice® HRD
Myriad's myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. High myChoice HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes, ovarian and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in certain patients with triple-negative breast and ovarian cancers. It is estimated that 1.8 million people in the United States and Europe who are diagnosed with cancers annually may be candidates for treatment with DNA-damaging agents.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the presentation of data from nine clinical studies at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill.; key podium presentations highlighting the safety and validity of the myRisk Hereditary multigene panel test in assessing hereditary cancer risk; the myRisk Hereditary Cancer studies presented at ASCO advancing the state-of-the-art of hereditary cancer testing; the new data providing additional evidence for the safety and clinical utility of the myRisk Hereditary Cancer test to help improve and save the lives of patients; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
Source:Myriad Genetics, Inc.